Literature DB >> 950686

Detection of adenovirus type 2-induced early polypeptides using cycloheximide pretreatment to enhance viral protein synthesis.

M L Harter, G Shanmugam, W S Wold, M Green.   

Abstract

(35S) methionine-labeled polypeptides synthesized by adenovirus type 2-infected cells have been analyzed by polyacrylamide gradient gel electrophoresis and autoradiography. Cycloheximide (CH) was added to infected cultures to accumulate early viral mRNA relative to host cell mRNA. This allowed viral proteins to be synthesized in increased amounts relative to host proteins after removal of CH and pulse-labeling with (35S)methionine. During the labeling period arabinosyl cytosine was added to prevent the synthesis of late viral proteins. This procedure facilitated the detection of six early viral-induced polypeptides, designated EP1 through EP6 (early protein), with apparent molecular weights of 75,000 (75K), 42K, 21K, 18K, 15K, and 11K. Supportive data were obtained by coelectrophoresis of (35S)- and (3H)methionine-labeled polypeptides from infected and uninfected cells, respectively. Three of these early polypeptides have not been previously reported. CH pretreatment enhanced the rates of synthesis of EP4 and EP6 20- to 30-fold and enhanced that of the others approximately twofold. The maximal rates of synthesis of the virus-induced proteins varied, in a different manner, with time postinfection and CH pretreatment. Since CH pretreatment appears to increase the levels of early viral proteins, it may be a useful procedure to assist their isolation and functional characterization.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 950686      PMCID: PMC354851     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  20 in total

1.  RNA synthesis and processing in adenovirus-infected cells.

Authors:  L Philipson; U Pettersson; U Lindberg; C Tibbetts; B Vennström; T Persson
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1975

2.  Adenovirus polypeptide synthesis in the presence of non-replicating poliovirus.

Authors:  R Bablanian; W C Russell
Journal:  J Gen Virol       Date:  1974-08       Impact factor: 3.891

3.  Immunological studies on viral polypeptide synthesis in cells replicating murine sarcoma-leukemia virus.

Authors:  G Shanmugam; G Vecchio; D Attardi; M Green
Journal:  J Virol       Date:  1972-09       Impact factor: 5.103

Review 4.  Oncogenic viruses.

Authors:  M Green
Journal:  Annu Rev Biochem       Date:  1970       Impact factor: 23.643

5.  Effect of cycloheximide on RNA metabolism early in productive infection with adenovirus 2.

Authors:  E A Craig; H J Raskas
Journal:  J Virol       Date:  1974-07       Impact factor: 5.103

6.  The polypeptides of adenovirus. IV. Detection of early and late virus-induced polypeptides and their distribution in subcellular fractions.

Authors:  G Walter; J V Maizel
Journal:  Virology       Date:  1974-02       Impact factor: 3.616

7.  The polypeptides of adenovirus. VI. Early and late glycopolypeptides.

Authors:  M Ishibashi; J V Maizel
Journal:  Virology       Date:  1974-04       Impact factor: 3.616

8.  Thermolabile DNA binding proteins from cells infected with a temperature-sensitive mutant of adenovrius defective in viral DNA synthesis.

Authors:  P C Van Der Vliet; A J Levine; M J Ensinger; H S Ginsberg
Journal:  J Virol       Date:  1975-02       Impact factor: 5.103

9.  Isolation of DNA Strand-specific early messenger RNA species in cells infected by human adenovirus 2.

Authors:  W Büttner; Z Veres-Molnár; M Green
Journal:  Proc Natl Acad Sci U S A       Date:  1974-08       Impact factor: 11.205

10.  Processing of adenovirus 2-induced proteins.

Authors:  C W Anderson; P R Baum; R F Gesteland
Journal:  J Virol       Date:  1973-08       Impact factor: 5.103

View more
  27 in total

1.  The 11,600-MW protein encoded by region E3 of adenovirus is expressed early but is greatly amplified at late stages of infection.

Authors:  A E Tollefson; A Scaria; S K Saha; W S Wold
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

2.  The degradation sequence of adenovirus E1A consists of the amino-terminal tetrapeptide Met-Arg-His-Ile.

Authors:  R Simon; J D Richter
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

3.  Sequence of protein synthesis in cells infected by human cytomegalovirus: early and late virus-induced polypeptides.

Authors:  M F Stinski
Journal:  J Virol       Date:  1978-06       Impact factor: 5.103

4.  Subcellular distribution of newly synthesized virus-specific polypeptides in Moloney murine leukemia virus infected cells.

Authors:  G Shanmugam
Journal:  J Virol       Date:  1979-01       Impact factor: 5.103

5.  Purification and characterization of an early glycoprotein from adenovirus type 2-infected cells.

Authors:  H Persson; C Signäs; L Philipson
Journal:  J Virol       Date:  1979-03       Impact factor: 5.103

6.  Identification and purification of a protein encoded by the human adenovirus type 2 transforming region.

Authors:  M Green; K H Brackmann; M A Cartas; T Matsuo
Journal:  J Virol       Date:  1982-04       Impact factor: 5.103

7.  Adenovirus type 2 early polypeptides immunoprecipitated by antisera to five lines of adenovirus-transformed rat cells.

Authors:  W S Wold; M Green
Journal:  J Virol       Date:  1979-04       Impact factor: 5.103

8.  Multiple methylated cap sequences in adenovirus type 2 early mRNA.

Authors:  S I Hashimoto; M Green
Journal:  J Virol       Date:  1976-11       Impact factor: 5.103

9.  Novel deletion mutants that enhance a distant upstream 5' splice in the E3 transcription unit of adenovirus 2.

Authors:  S L Deutscher; B M Bhat; M H Pursley; C Cladaras; W S Wold
Journal:  Nucleic Acids Res       Date:  1985-08-26       Impact factor: 16.971

10.  Synthesis of human adenovirus early RNA species is similar in productive and abortive infections of monkey and human cells.

Authors:  K P Anderson; D F Klessig
Journal:  J Virol       Date:  1982-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.